These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of Adnan A; Basu S J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476 [TBL] [Abstract][Full Text] [Related]
5. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215 [TBL] [Abstract][Full Text] [Related]
6. Discordant Uptake Between Diagnostic 68Ga-HA-DOTATATE PET/CT and Posttherapy 177Lu-HA-DOTATATE SPECT/CT in Patients With Neuroendocrine Tumors. Huizing DMV; Aalbersberg EA; van der Hiel B; Stokkel MPM; Versleijen MWJ Clin Nucl Med; 2021 Sep; 46(9):e475-e477. PubMed ID: 33782314 [TBL] [Abstract][Full Text] [Related]
7. Parghane RV; Talole S; Basu S Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123 [TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914 [TBL] [Abstract][Full Text] [Related]
9. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT? Zemczak A; Kołodziej M; Gut P; Królicki L; Kos-Kudła B; Kamiński G; Ruchała M; Pawlak D; Kunikowska J Endokrynol Pol; 2020; 71(3):240-248. PubMed ID: 32293704 [TBL] [Abstract][Full Text] [Related]
10. 177 Lu-DOTATATE PRRT for Multiple Unusual Metastatic Sites in Neuroendocrine Tumor. Parghane RV; Basu S Clin Nucl Med; 2022 Oct; 47(10):874-875. PubMed ID: 35353741 [TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation. Jois B; Asopa R; Basu S Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668 [TBL] [Abstract][Full Text] [Related]
12. Different technical possibilities of post-therapeutic tandem 90Y/ /177Lu-DOTATATE imaging. Kunikowska J; Bajera A; Sawicka M; Czwarnowski P; Pawłowicz B; Aksamit D; Pawlak D; Królicki L Nucl Med Rev Cent East Eur; 2013; 16(2):70-4. PubMed ID: 24068636 [TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor radionuclide therapy in neuroendocrine tumors. Haider M; Das S; Al-Toubah T; Pelle E; El-Haddad G; Strosberg J Endocr Relat Cancer; 2021 Mar; 28(3):R81-R93. PubMed ID: 33608483 [TBL] [Abstract][Full Text] [Related]
14. Squamous Cell Carcinoma Mimicking Neck Paraganglioma on 68Ga-DOTATATE PET/CT. Civan C; Isik EG; Has Simsek D; Sen C; Unal SN Clin Nucl Med; 2021 Jul; 46(7):e368-e370. PubMed ID: 33630807 [TBL] [Abstract][Full Text] [Related]
15. Diagnosis and Treatment of Lung Neuroendocrine Neoplasms: Somatostatin Receptor PET Imaging and Peptide Receptor Radionuclide Therapy. Park H; Subramaniam RM PET Clin; 2023 Apr; 18(2):223-231. PubMed ID: 36585338 [TBL] [Abstract][Full Text] [Related]
16. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms. Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939 [TBL] [Abstract][Full Text] [Related]
17. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704 [TBL] [Abstract][Full Text] [Related]
18. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Hindié E Theranostics; 2017; 7(5):1159-1163. PubMed ID: 28435455 [TBL] [Abstract][Full Text] [Related]
19. Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma. Dadgar H; Jafari E; Ahmadzadehfar H; Rekabpour SJ; Ravanbod MR; Kalantarhormozi M; Nabipour I; Assadi M Ann Endocrinol (Paris); 2023 Feb; 84(1):45-51. PubMed ID: 36126757 [TBL] [Abstract][Full Text] [Related]
20. Sequential Duo-Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors: Posttherapy Bremsstrahlung and PET/CT Imaging Following 90Y-DOTATATE Treatment. Parghane RV; Mitra A; Upadhye T; Rakshit S; Banerjee S; Basu S Clin Nucl Med; 2020 Sep; 45(9):714-715. PubMed ID: 32657872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]